Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Ibrahim Haznedaroglu, Kimmo Porkka, Elisabetta Abruzzese, Giuliana Alimena, Hans Ehrencrona, Henrik Hjorth-Hansen, Veli Kairisto, Luciano Levato, Giovanni Martinelli, Arnon Nagler, Johan Lanng Nielsen, Ugur Ozbek, Francesca Palandri, Fausto Palmieri, Fabrizio Pane, Giovanna Rege-Cambrin, Domenico Russo, Giorgina Specchia, Nicoletta Testoni, Ole Weiss-Bjerrum, Giuseppe Saglio, Bengt Simonsson, Michele Baccarani, Gianantonio Rosti, Fausto Castagnetti, Ibrahim Haznedaroglu, Kimmo Porkka, Elisabetta Abruzzese, Giuliana Alimena, Hans Ehrencrona, Henrik Hjorth-Hansen, Veli Kairisto, Luciano Levato, Giovanni Martinelli, Arnon Nagler, Johan Lanng Nielsen, Ugur Ozbek, Francesca Palandri, Fausto Palmieri, Fabrizio Pane, Giovanna Rege-Cambrin, Domenico Russo, Giorgina Specchia, Nicoletta Testoni, Ole Weiss-Bjerrum, Giuseppe Saglio, Bengt Simonsson
Abstract
Imatinib mesylate (IM), 400 mg daily, is the standard treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML). Preclinical data and results of single-arm studies raised the suggestion that better results could be achieved with a higher dose. To investigate whether the systematic use of a higher dose of IM could lead to better results, 216 patients with Ph(+) CML at high risk (HR) according to the Sokal index were randomly assigned to receive IM 800 mg or 400 mg daily, as front-line therapy, for at least 1 year. The CCgR rate at 1 year was 64% and 58% for the high-dose arm and for the standard-dose arm, respectively (P = .435). No differences were detectable in the CgR at 3 and 6 months, in the molecular response rate at any time, as well as in the rate of other events. Twenty-four (94%) of 25 patients who could tolerate the full 800-mg dose achieved a CCgR, and only 4 (23%) of 17 patients who could tolerate less than 350 mg achieved a CCgR. This study does not support the extensive use of high-dose IM (800 mg daily) front-line in all CML HR patients. This trial was registered at www.clinicaltrials.gov as #NCT00514488.
Source: PubMed